Trexquant Investment LP boosted its stake in shares of Chemed Corporation (NYSE:CHE - Free Report) by 51.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,628 shares of the company's stock after buying an additional 5,978 shares during the period. Trexquant Investment LP owned 0.12% of Chemed worth $10,847,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CHE. Marshall Wace LLP acquired a new position in Chemed during the fourth quarter worth $618,000. Northern Trust Corp lifted its stake in shares of Chemed by 19.3% in the 4th quarter. Northern Trust Corp now owns 208,535 shares of the company's stock valued at $110,482,000 after purchasing an additional 33,710 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Chemed by 18.0% in the 4th quarter. AQR Capital Management LLC now owns 80,665 shares of the company's stock valued at $42,736,000 after purchasing an additional 12,300 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in shares of Chemed by 16.3% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 520 shares of the company's stock valued at $275,000 after purchasing an additional 73 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Chemed by 112.9% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 10,460 shares of the company's stock valued at $5,542,000 after purchasing an additional 5,548 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.
Chemed Trading Down 1.1%
CHE traded down $5.00 during mid-day trading on Wednesday, hitting $459.00. 99,329 shares of the stock were exchanged, compared to its average volume of 139,832. The firm's fifty day moving average is $459.55 and its two-hundred day moving average is $536.02. Chemed Corporation has a 1-year low of $408.42 and a 1-year high of $623.60. The company has a market cap of $6.69 billion, a PE ratio of 23.60, a PEG ratio of 2.52 and a beta of 0.46.
Chemed (NYSE:CHE - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.02 by ($1.75). The firm had revenue of $618.80 million for the quarter, compared to analyst estimates of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%.Chemed's revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company posted $5.47 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, research analysts anticipate that Chemed Corporation will post 21.43 earnings per share for the current year.
Chemed Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 11th were given a $0.60 dividend. The ex-dividend date of this dividend was Monday, August 11th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. This is an increase from Chemed's previous quarterly dividend of $0.50. Chemed's dividend payout ratio is 12.34%.
Insider Transactions at Chemed
In other Chemed news, EVP Nicholas Michael Westfall sold 10,012 shares of the stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $421.91, for a total value of $4,224,162.92. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director George J. Walsh III purchased 200 shares of Chemed stock in a transaction on Monday, August 4th. The stock was bought at an average cost of $417.10 per share, for a total transaction of $83,420.00. Following the transaction, the director directly owned 3,523 shares in the company, valued at $1,469,443.30. This represents a 6.02% increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.29% of the stock is owned by company insiders.
Analyst Ratings Changes
CHE has been the topic of several recent analyst reports. Wall Street Zen lowered Chemed from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. Oppenheimer decreased their price target on Chemed from $650.00 to $580.00 and set an "outperform" rating on the stock in a research note on Thursday, July 31st. Royal Bank Of Canada decreased their price target on Chemed from $640.00 to $589.00 and set an "outperform" rating on the stock in a research note on Thursday, July 31st. Jefferies Financial Group raised Chemed from a "hold" rating to a "buy" rating and upped their price target for the company from $490.00 to $550.00 in a research note on Tuesday. Finally, Bank of America decreased their target price on Chemed from $708.00 to $650.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Chemed currently has a consensus rating of "Buy" and an average price target of $592.25.
Check Out Our Latest Stock Analysis on Chemed
Chemed Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Featured Articles

Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.